Renal Cancer - Results from #180

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03). December 2, 2022

Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. December 2, 2022

A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy. December 1, 2022

Pediatric Small Renal Masses: Can Tumor Size Predict Histology and the Potential for Nephron-Sparing Surgery? December 1, 2022

Cancer-specific Mortality After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma. November 30, 2022

Stereotactic Body Radiotherapy for Kidney Cancer: Ready for Prime Time? November 30, 2022

Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. November 29, 2022

Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study. November 29, 2022

European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View. November 29, 2022

Prognostic model for overall survival that includes the combination of platelet count and neutrophil-lymphocyte ratio within the first six weeks of sunitinib treatment for metastatic renal cell carcinoma. November 28, 2022

The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape. November 28, 2022

Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma. November 25, 2022

Preoperative neutrophil-lymphocyte ratio/platelet-lymphocyte ratio: A potential and economical marker for renal cell carcinoma. November 25, 2022

End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. November 24, 2022

Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. November 24, 2022

French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. November 23, 2022

Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer. November 23, 2022

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). November 22, 2022

Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma. November 22, 2022

Quality-of-life reporting in randomized controlled trials shaping the EAU Renal Cell Carcinoma Guidelines. November 21, 2022

Page 10 of 405